The U.S. Food and Drug Administration has granted accelerated approval to subcutaneous amivantamab with hyaluronidase-lpuj for a narrowly defined group of adults with recurrent or metastatic head and neck squamous cell carcinoma. The decision creates a new option after two major treatment approaches have already failed, but it is not a broad approval for every head and neck cancer.
Who is covered by the approval?
The indication applies to adults whose cancer has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. It does not include people with HPV-associated oropharyngeal squamous cell carcinoma. Treatment is given by a subcutaneous injection on a weight-based schedule every three weeks.
What evidence supported the decision?
The FDA based the decision on OrigAMI-4, an open-label, multicohort clinical trial. The primary analysis included 102 patients. A blinded independent review found an overall response rate of 42%, with a 95% confidence interval from 32% to 52%. Among people who responded, 56% had a response lasting at least six months.
Those results describe tumor response and its duration. They do not yet establish that the medicine helps people live longer or improves quality of life. Because this is an accelerated approval, continued approval may depend on a confirmatory trial that verifies clinical benefit.
Important safety issues
The prescribing information includes warnings about hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, skin reactions, eye toxicity and harm to a developing fetus. Decisions about treatment require an oncology team to weigh the potential benefit against these risks, other medical conditions and prior treatments.
Why the word “accelerated” matters
Accelerated approval allows the FDA to act on an earlier measure that is considered reasonably likely to predict clinical benefit for a serious condition with unmet need. It is not the same as a completed demonstration of long-term benefit. The agency lists an ongoing randomized study intended to confirm the result, with a projected completion in 2029.
Questions patients can bring to an appointment
- Does my cancer match the exact approved indication?
- Which treatments have I already received, and how does that affect eligibility?
- What are the most important side effects for my health history?
- How will the care team monitor lung, skin and eye symptoms?
- What other approved treatments or clinical trials should we compare?
This article is for general information and does not replace medical advice. Cancer treatment should be discussed with a qualified oncology team.
